Life Sciences & MOBs Maintain Resilience Amidst Market Headwinds

By Majid Radaei, RadCRE · 2026-05-09 · Industry Insights

Despite broader CRE turbulence, life sciences and medical office buildings (MOBs) continue to attract significant investment, with Q1 2026 transaction volumes demonstrating sustained demand for these recession-resistant asset classes.

Resilience of Life Sciences and Medical Office Niche

In a commercial real estate landscape marked by fluctuating interest rates and re-evaluation across traditional asset classes, the life sciences and medical office building (MOB) sectors have continued to exhibit remarkable resilience and attract significant investor capital. These specialized property types benefit from long-term demographic trends, such as an aging population and scientific innovation, rendering them less susceptible to economic cycles.

Recent data from MSCI Real Assets (formerly Real Capital Analytics) indicates that while overall CRE transaction volumes saw a year-over-year decline in Q1 2026, the life sciences sector demonstrated comparative stability. For instance, BioMed Realty, a Blackstone portfolio company, recently announced the groundbreaking of its new 400,000 square foot life sciences facility in Cambridge, MA, underscoring ongoing developer and tenant confidence in core innovation hubs. Similarly, institutional players like Starwood Capital have continued to deepen their investments, with Starwood Property Trust recently closing on a significant medical office portfolio acquisition valued at approximately $750 million, further solidifying the sector's appeal.

Investment Demand and Capital Deployment

The demand for life sciences and MOB assets is driven by their defensible income streams and historically low volatility. Medical office buildings, in particular, often feature long-term leases with creditworthy healthcare providers, offering stability that is highly sought after by institutional investors. Cap rates for prime MOB assets have remained tighter than many other property types, often ranging from 5.5% to 6.5% for core assets, although these can vary significantly by market and tenancy.

Innovation clusters continue to draw the lion's share of life sciences investment. Boston/Cambridge, the San Francisco Bay Area, and San Diego remain dominant, with emerging markets like Raleigh-Durham and Philadelphia also expanding rapidly. According to JLL’s Q4 2025 Life Sciences Outlook, venture capital funding for biotech companies remained robust, translating into sustained demand for specialized lab and R&D space. Despite a slight cooling from the peak of 2021-2022, VC funding still significantly outpaces pre-pandemic levels, fueling a strong development pipeline in key clusters.

Financing for these specialized assets also reflects investor confidence. While broader construction lending has tightened, lenders remain more amenable to projects backed by strong pre-leasing commitments from reputable life sciences tenants or healthcare systems. Bridge financing for value-add MOB plays typically ranges from SOFR + 300-500 bps, while stabilized, high-quality portfolios can secure more favorable terms closer to SOFR + 200-300 bps through conventional or agency channels. CMBS markets, though selective, have also seen successful securitizations of healthcare and life science-backed loans, albeit with spreads for these specialty assets often commanding a premium compared to traditional multifamily or retail, in the T + 175-300 bps range, depending on leverage and property subtype.

In today’s volatile market, life sciences and medical office are not just defensive plays; they are strategic investments. We’re seeing institutional capital, some of it previously allocated to sectors now facing headwinds, aggressively pivot here. While some investors fear a 'wall of maturities' across other asset classes, the underlying demand drivers for MOBs – an aging population and increasing healthcare spend – are non-negotiable. For life sciences, it’s about aligning with the future of innovation. What we advise clients on is differentiating true innovation hubs with robust VC funding and talent pools from aspirational markets. Not all 'life science' space is created equal, and not all MOBs offer the same lease stability. It's about granular underwriting of tenant credit, lease structures, and the economic fundamentals of the specific submarket. We're also seeing attractive financing solutions emerge for well-sponsored projects in these sectors, especially bridge-to-perm strategies that capitalize on current acquisition pricing but anticipate future rate declines.

Outlook and Future Considerations

The outlook for life sciences and MOBs remains positive, albeit with careful consideration of specific market dynamics. While the capital markets have become more discerning, the fundamental drivers powering these sectors are intact. The increasing integration of telemedicine and wellness offerings may also drive demand for smaller, strategically located medical office spaces in suburban areas, expanding the investment landscape beyond traditional urban medical corridors. RadCRE continues to advise clients on navigating these complex markets, identifying opportunities in both core and value-add strategies across the life sciences and healthcare real estate continuum, leveraging our deep underwriting capabilities and extensive lender relationships for specialized financing.

Tags: life sciences real estate, medical office buildings, CRE investment, RadCRE, healthcare real estate, commercial real estate financing, institutional investment

Sources: MSCI Real Assets, JLL, Commercial Observer, CoStar News, Starwood Capital Group Public Filings